Bioventus Inc. (BVS) – What Are Investment Firms Thinking About This Stock?

Shares of Bioventus Inc. (NASDAQ:BVS) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $16.80.

Several brokerages recently issued reports on BVS. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, August 17th. Craig Hallum reissued a “buy” rating and issued a $18.00 target price on shares of Bioventus in a report on Thursday, August 6th. Weiss Ratings upgraded Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Barrington Research set a $18.00 target price on Bioventus in a report on Thursday, August 6th. Finally, Canaccord Genuity Group increased their price target on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 17th.

Bioventus Stock Up 1.5%

BVS stock opened at $14.87 on Friday. Bioventus has a twelve month low of $6.47 and a twelve month high of $15.89. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.25 billion, a P/E ratio of 19.28, a PEG ratio of 1.87 and a beta of 0.64. The firm has a 50 day simple moving average of $13.72 and a 200-day simple moving average of $10.85.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The company had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts predict that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

Large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Bioventus by 14.1% during the first quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after buying an additional 107,930 shares during the period. Hillsdale Investment Management Inc. increased its holdings in shares of Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after purchasing an additional 401,230 shares during the period. Engine Capital Management LP acquired a new stake in Bioventus in the first quarter worth about $2,876,000. Lazard Asset Management LLC grew its position in Bioventus by 12.9% in the 1st quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock valued at $2,789,000 after buying an additional 35,008 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after buying an additional 178,539 shares during the period. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.